Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home News room Press releases
Press Releases

2010

25/02/2010
ABLYNX ANNOUNCES 2009 FULL YEAR RESULTS
NL

22/02/2010
ABLYNX RESPONDS TO PRESS REPORTS
NL

22/02/2010
ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2009 WITH WEBCAST
NL

19/02/2010
ABLYNX RECEIVES €1.2 MILLION GRANT TO FURTHER ADVANCE ITS ANTI-IL-6R PROGRAMME, ALX-0061
NL

11/02/2010
ABLYNX WINS PATENT OPPOSITION CASE AGAINST DOMANTIS (GSK)
NL

11/02/2010
ABLYNX SELECTS GPCR TARGETING DEVELOPMENT CANDIDATE, ANNOUNCES NEW DATA ON ALTERNATIVE ROUTES OF DELIVERY FOR NANOBODIES AND PROVIDES AN R&D UPDATE
NL

22/01/2010
ABLYNX ANNOUNCES WARRANT EXERCISE
NL

11/01/2010
ABLYNX SUCCESSFULLY GENERATES NANOBODIES® AGAINST AN ION CHANNEL AND ANNOUNCES NEW GPCR PROGRAMME
NL

06/01/2010
ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 28TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
NL








































 

Press releases

  • 2010

News archive

Email alerts

If you would like to receive updates on the company news, please
click here